TABLE 3.
Kaplan–Meier estimates of clinical outcomes at 12 months
| Overall, N = 1,075 | NSTEMI, N = 206 | Diabetes, N = 228 | Type B2/C lesions, N = 164 | |
|---|---|---|---|---|
| TLF | 45 (4.3%) [3.2;5.7] | 12 (6.1%) [3.5;10.6] | 10 (4.7%) [2.5;8.7] | 9 (5.7%) [3.0;10.6] |
| Cardiac death | 2 (0.2%) [0.0;0.7] | 0 | 1 (0.4%) [0.1;3.1] | 1 (0.6%) [0.1;4.3] |
| TV‐myocardial infarction | 12 (1.1%) [0.6;2.0] | 6 (2.9%) [1.3;6.4]a | 4 (1.8%) [0.7;4.6] | 2 (1.3%) [0.3;4.9] |
| Clinically driven TLR | 39 (3.9%) [2.9;5.3] | 11 (5.6%) [3.1;10.0] | 8 (3.8%) [1.9;7.7] | 9 (5.7%) [3.0;10.6] |
| Death | 7 (0.7%) [0.3;1.4] | 1 (0.5%) [0.1;3.4] | 3 (1.3%) [0.4:4.0] | 2 (1.3%) [0.3;5.0] |
| Myocardial infarction | 13 (1.2%) [0.7;2.1] | 7 (3.4%) [1.6;7.0] | 4 (1.8%) [0.7:4.6] | 2 (1.3%) [0.3;4.9] |
| CD‐TVR | 44 (4.2%) [3.2;5.6] | 11 (5.6%) [3.1;10.0] | 8 (3.8%) [1.9;7.7] | 9 (5.7%) [3.0;10.6] |
| TVF | 48 (4.6%) [3.5;6.0] | 12 (6.1%) [3.5;10.6] | 10 (4.7%) [2.5;8.7] | 9 (5.7%) [3.0;10.6] |
| Stent thrombosis | ||||
| Definite | 5 (0.5%) [0.2;1.1] | 2 (1.0%) [0.2;3.8] | 2 (0.9%) [0.2;3.5] | 1 (0.6%) [0.1;4.3] |
| Definite/probable | 5 (0.5%) [0.2;1.1] | 2 (1.0%) [0.2;3.8] | 2 (0.9%) [0.2;3.5] | 1 (0.6%) [0.1;4.3] |
Note: Data are shown as n (Kaplan–Meier estimate in %) [95%CI].
Abbreviations: CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; NSTEMI, non‐ST‐elevation myocardial infarction; TLF, target lesion revascularization; TLR, target lesion revascularization; TV, target vessel; TVF, target‐vessel failure; TVR, target‐vessel revascularization.
a
Significantly different to non‐NSTEMI patients.